AstraZeneca Plc laid out its defence against Pfizer Inc's $106 billion takeover approach on Tuesday, painting a bullish picture of its new drug pipeline and forecasting sales above $45 billion by 2023.Britain's second biggest drugmaker recorded sales of $25.7 billion in 2013.While AstraZeneca faces declining revenue over the next three years as older medicines lose patent protection, the company said it sees "strong and consistent" growth from 2017 to 2023, driven by new treatments for cancer, diabetes, heart disease and lung disorders.Growth in core earnings per share, which excludes certain items, is expected to exceed revenue growth during this period, it added.
AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. Shares of AZN fell by 1.42% or $-1.15/share to $79.87. In the past year, the shares have traded as low as $46.87 and as high as $82.68. On average, 3546180 shares of AZN exchange hands on a given day and today's volume is recorded at 5813624.
Source
